Avacta (AIM: AVCT) raises £9m at no discount days after ASCO cancer data

Avacta Therapeutics (AIM: AVCT) has raised approximately £9 million in an oversubscribed equity placing priced at 70 pence per share, the exact closing mid-market price the day before, which means existing holders took no discount hit. The clinical-stage biopharma placed 12,792,859 new shares, with a single institutional cornerstone investor providing most of the money and chief executive Christina Coughlin and non-executive director Mark Goldberg each putting in about £22,500 of their own cash. The raise lands just four days after Avacta presented updated AVA6000 data at the 2026 ASCO meeting in Chicago showing continued anti-tumour activity in salivary gland cancers and a cardiac safety profile clean enough for regulators to lift the drug’s lifetime dosing cap. Both events are timed against a hard deadline: a convertible bond clause that lets the bondholder accelerate deferred repayments after 30 June 2026. With the stock trading in the mid-70s pence against a 52-week range of roughly 28p to 92p, the market is treating this as a company buying itself room rather than one in distress.

What does Avacta actually do and why is the pre|CISION platform different from normal chemo?

Avacta’s whole pitch rests on a simple problem with an old drug. Doxorubicin is a potent chemotherapy that works, but it poisons the heart, which is why oncologists cap how much a patient can ever receive over a lifetime. Avacta’s pre|CISION platform attaches the drug to a peptide that stays inert until it hits an enzyme called fibroblast activation protein, or FAP, which is heavily present in most solid tumours and scarce in healthy tissue. The idea is that the active drug only switches on inside the tumour, sparing the rest of the body.

That is the differentiation in plain terms. AVA6000, also called faridoxorubicin, is the first-generation version of this and the lead asset. The company is running a second-generation candidate, AVA6103, and pushing a third-generation molecule toward IND-enabling studies, so pre|CISION is meant to be a platform that spawns many drugs rather than a single bet. For a retail investor, the thing to hold onto is that the value here is the platform validating, not just one trial reading out.

The risk worth naming early is that this is still Phase 1. A FAP-activation mechanism that looks elegant in a deck has to keep proving it concentrates payload in tumours across many cancer types, and partnering interest only converts into real money if larger trials confirm the early signal.

How strong is the AVA6000 salivary gland cancer data and what does the lifted dosing cap really mean?

The headline numbers from ASCO were respectable for an early trial. Among 38 evaluable salivary gland cancer patients dosed at the recommended expansion dose of 310 mg/m2, Avacta reported four confirmed partial responses and nine minor responses, with a disease control rate of 92 percent, meaning 35 of 38 patients held stable or better. Salivary gland cancer matters as a target because it is rare, slow to respond to conventional chemo, and has few approved options, so even modest activity gets attention.

The more strategically important development was the safety read. Across 111 patients dosed to date, fewer than four percent showed meaningful drops in heart function and no cardiomyopathy of any grade was recorded, even in patients who had passed the old 550 mg/m2 lifetime ceiling. After reviewing the exposure data, a health authority agreed to remove that lifetime maximum from the study protocol. In practice that means patients could stay on the drug longer, which both improves the clinical story and widens the eventual commercial case if doxorubicin’s signature toxicity really has been engineered out.

The skeptical reading is that response numbers are still small and early, partial and minor responses are not the same as durable complete responses, and a single rare cancer cohort does not yet prove the platform works broadly. The next two catalysts, further data at the BIO International Convention from 22 to 25 June and the eventual triple negative breast cancer readout, will matter more for whether this scales beyond a niche indication.

Why did Avacta raise equity at full price instead of taking a discount, and what does the convertible bond clause force?

This is where the financing and the clinical story connect, and it is the sharpest part of the whole setup. Avacta carries a convertible bond, and back in August 2025 it deferred certain repayments and interest from January and April 2026 out to October 2027. The catch is that the bondholder gained the right to accelerate those deferred amounts after the earlier of two events: Avacta publishing Phase 1b breast cancer data for AVA6000, or 30 June 2026.

The dilution math explains the 70p raise. If those deferred repayments had been settled in shares, the reference prices baked into the bond terms were around 48.75p and 64.65p, both below where the stock now trades. Issuing fresh equity at 70p to repay in cash instead is therefore cheaper for existing shareholders than letting the bond convert at those lower reference levels. Management has said accelerated repayment could cut the outstanding bond to roughly £11.5 million. Pricing the placing at zero discount to market, rather than the usual mid to high single-digit discount AIM placings carry, signals that demand was genuine and that the cornerstone investor was willing to pay up.

For investors the read is twofold. The good news is the company is actively managing a debt structure that has clearly weighed on the equity and chosen the lower-dilution path. The caution is that this is the latest in a sequence of raises, including a £16 million placing in October 2025, and clinical-stage biotechs that repeatedly tap the market for cash to service debt are running a clock that only stops when a partnering deal or pivotal data arrives. The accompanying block listing application to AIM is routine administrative housekeeping to admit the new shares, not a separate fundraising event, so it should not be read as further dilution on top.

How is the market pricing AVCT against the newsflow and what are forums actually saying?

The price action tells a recovery story with a ceiling. AVCT changed hands in the mid-70s pence in early June against a 52-week low near 28p and a high around 92p, putting it well off the bottom but still short of its peak. Market capitalisation sits in the region of £310 million to £325 million on roughly 455 million shares. Analyst views are split: some carry buy ratings with price targets in the 80p to 100p-plus range, while at least one data house has tagged the stock a momentum trap with a consensus target below the current price, which captures the tension neatly. The fundamentals are early and loss-making, but the narrative momentum is real.

Retail conversation reflects exactly that divide. Supporters point to a placing done at no discount with director participation as a confidence signal, and to the cardiac safety data as the genuine breakthrough. The bears are blunter, framing the convertible as a death-spiral structure and warning that holders will keep getting diluted until Avacta clears a meaningful Phase 2 hurdle. Both camps are arguing about the same fact pattern, which is usually the sign of a stock where the next catalyst, not the last one, sets the price.

The honest investor takeaway is that AVCT remains a binary, catalyst-driven name. The June BIO data and the breast cancer readout are the events that decide whether the platform thesis gets repriced upward or whether the market keeps treating each raise as a warning light.

Key takeaways on what the Avacta raise and ASCO data mean for shareholders and the pipeline

• Avacta raised about £9 million at 70p with zero discount to market, a stronger signal of demand than the discounted placings typical on AIM.
• The raise exists primarily to repay convertible bond obligations in cash and dodge share conversion at lower reference prices near 48.75p and 64.65p, reducing dilution.
• Accelerated repayment could shrink the outstanding bond to roughly £11.5 million, materially de-risking the balance sheet ahead of the 30 June trigger date.
• The ASCO salivary gland cancer data showed four partial and nine minor responses among 38 patients with a 92 percent disease control rate, solid for an early trial but not yet definitive.
• The bigger clinical win was cardiac safety: removal of doxorubicin’s lifetime dosing cap after a regulator accepted the exposure analysis, which strengthens both the medical and commercial case.
• Value sits in the pre|CISION platform validating across AVA6000, AVA6103 and a third-generation candidate, not in any single cohort.
• Director participation from the CEO and a non-executive adds an insider-confidence signal, though the sums involved are modest.
• The stock has recovered sharply from its 28p low but trades well below its 92p high, with analyst opinion genuinely split between buy and momentum-trap framings.
• Near-term catalysts are the BIO International data from 22 to 25 June 2026 and the eventual triple negative breast cancer readout.
• This remains a binary, financing-dependent biotech where the next catalyst, not the last raise, will set direction.